![SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC](https://www.urotoday.com/images/Lu-PSMA.png)
SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC
![SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC](https://www.urotoday.com/images/cabazitaxel_SNMMI.png)
SNMMI 2021: The Phase 3 VISION Trial: Evaluating the Efficacy of 177-Lu-PSMA (LuPSMA) in the Treatment of Patients with PSMA-Positive mCRPC
![Sloan Kettering Paid $1.5 Million Severance to a Cancer Doctor Forced Out Over Conflicts - The New York Times Sloan Kettering Paid $1.5 Million Severance to a Cancer Doctor Forced Out Over Conflicts - The New York Times](https://static01.nyt.com/images/2020/12/22/science/22MSK-CONFLICT1/merlin_149030190_98659b59-08c9-46a8-a3e7-3bb692351ec6-articleLarge.jpg?quality=75&auto=webp&disable=upscale)